𝔖 Bobbio Scriptorium

✦ LIBER ✦

Infliximab dose escalation not uncommon during first year in RA

Book ID: 120851710
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2006
Weight: 138 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200615200-00013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early clinical remission and normalisati

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

✍ L. S. Kiss; T. Szamosi; T. Molnar; P. Miheller; L. Lakatos; A. Vincze; K. Palatk 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 191 KB